title: Treatment of ocular motility disturbances in Graves' disease with botulinum toxin A.
abstract: The aim of this study was to evaluate the efficacy of botulinum toxin-A injections on motility disturbance in patients with dysthyroid eye disease. In 36 patients (52 orbits) with active phase of Grave's ophthalmopathy with motility disturbance, botulinum toxin-A injections were applied. Ocular motility was measured before and after treatment in four main directions (elevation, depression, abduction and adduction) with Förster perimeter. In all patients 20 units of botulinum toxin-A in one single injection was applied in the projection of the inferior rectus muscle. Statistically, the degree of upgaze increased notably in all three groups, but mostly in the first group where it amounted up to 5.8-6.0 (z = 10.0;p = 0.68). We could not prove notable increase of the motility grade in the adduction in none of the groups of the tested patients. Due to the fact that eyeball motility can be objectively measured, effect of the applied therapy can be clearly evaluated.
authors.affiliation: University Department of Ophthalmology, Clinical Hospital, Rebro, Zagreb, Croatia. nedastig@mef.hr
authors.forename: Neda
authors.initials: N
authors.lastname: Stiglmayer
authors.forename: Mladen
authors.initials: M
authors.lastname: Lesin
authors.forename: Jelena
authors.initials: J
authors.lastname: Juri
authors.forename: Milan
authors.initials: M
authors.lastname: Ivanisević
authors.forename: Lovro
authors.initials: L
authors.lastname: Boić
authors.forename: Veljko
authors.initials: V
authors.lastname: Rogosić
mesh_terms: D000328:Adult; D000368:Aged; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D005260:Female; D006111:Graves Disease / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009465:Neuromuscular Agents / Q000627:therapeutic use*; D015835:Ocular Motility Disorders / Q000188:drug therapy*; D011446:Prospective Studies; D018709:Statistics, Nonparametric
chemical_list: D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A